Across TCGA pan-cancer cohorts, MRPL20-AS1 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated MRPL20-AS1 data layer.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MRPL20-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MRPL20-AS1 expression acts as an unfavorable survival marker, although some lineages such as MESO and CHOL show a favorable association.
KIRC, ACC, and LGG are the cancer types where MRPL20-AS1 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.